메뉴 건너뛰기




Volumn 22, Issue 19, 2012, Pages 6173-6180

JD-5006 and JD-5037: Peripherally restricted (PR) cannabinoid-1 receptor blockers related to SLV-319 (Ibipinabant) as metabolic disorder therapeutics devoid of CNS liabilities

Author keywords

CB1 antagonist; CB1 receptor inverse agonist; Diabetes; Dyslipidemias; JD 5006; JD 5037; Liver diseases; Metabolic disorders; Obesity; Peripherally restricted cannabinoid 1 receptor blockers; Rimonabant; SLV 319

Indexed keywords

3 (4 CHLOROPHENYL) N' [(4 CHLOROPHENYL)SULFONYL] N (ACETAMIDE) 4 PHENYL 4,5 DIHYDRO 1H PYRAZOLE 1 CARBOXAMIDINE; 3 (4 CHLOROPHENYL) N' [(4 CHLOROPHENYL)SULFONYL] N [(ISOPROPYL)ACETAMIDE] 4 PHENYL 4,5 DIHYDRO 1H PYRAZOLE 1 CARBOXAMIDINE; CANNABINOID 1 RECEPTOR ANTAGONIST; IBIPINABANT; JD 5006; JD 5037; LIVER ENZYME; RIMONABANT; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

EID: 84866415138     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2012.08.004     Document Type: Article
Times cited : (78)

References (45)


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.